Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from SUPN

3 Pharma Stocks Poised for Big Returns This Summer

The pharmaceutical industry is expected to grow rapidly due to the ever-rising healthcare needs and the incorporation of cutting-edge technologies into drug manufacturing. Hence, pharma stocks Eli Lilly (LLY), Green Thumb Industries (GTBIF), and Supernus Pharmaceuticals (SUPN) might be worth buying for returns this summer. Read more….

StockNews.com

3 Pharma Stocks to Buy for Potential Financial Fortunes

Amid surging medicine demand and ongoing drug shortages, the pharmaceutical industry thrives, driving improved patient outcomes and promising growth opportunities for investors. So, it could be wise to invest in quality pharma stocks ACADIA Pharmaceuticals (ACAD), Neurocrine Biosciences (NBIX), and Supernus Pharmaceuticals (SUPN), which can help you fetch potential financial…

StockNews.com

3 Lucrative Pharma Stocks to Diversify Your Investments

The pharma industry’s resilience and long-term prospects are driven by rising healthcare demand, an enhanced focus on precision medicines, and technological advancements. Hence, let’s take a look at pharma stocks Perrigo Company (PRGO), Amneal Pharmaceuticals (AMRX), and Supernus Pharmaceuticals (SUPN), which could diversify your investments. Read on….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharma Stocks to Anchor Your Portfolio

The pharma market is poised to thrive due to the continuous medicinal advancements to meet the escalating demand for chronic disease treatment, technological advancements, and increased research and development. Given this backdrop, quality pharma stocks Procaps Group S.A. (PROC), Supernus Pharmaceuticals (SUPN), and GSK plc (GSK) could be wise portfolio…

StockNews.com

3 Lucrative Pharma Stocks for Portfolio Success

The pharmaceutical industry holds immense promise due to the rapidly aging population, growing healthcare needs, breakthroughs in new drugs and therapies, and the rise in chronic diseases. Therefore, it could be wise to add fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Eton Pharmaceuticals (ETON), and Viatris (VTRS) to one’s portfolio.…

StockNews.com

3 Pharma Stocks to Buy Before Year-End

Amid rising global medical needs, the pharmaceutical industry is expected to witness robust growth in the coming years. Given the solid long-term prospects of the industry, fundamentally sound pharma stocks Spero Therapeutics (SPRO), Astellas Pharma (ALPMY) and Supernus Pharmaceuticals (SUPN) could be ideal buys for steady gains. Read on.

StockNews.com

3 Rising Pharma Stocks to Consider Buying Now

The pharmaceutical sector is transforming due to the swift uptake of digital solutions and worldwide spending growth. Hence, fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Astellas Pharma (ALPMY), and Eli Lilly (LLY) might be solid buys now. Read more….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Undervalued Pharma Stocks Worth Buying

With the growing prevalence of chronic diseases, the adoption of advanced digital technologies, and new drug discoveries, the pharmaceutical industry is set to witness significant growth this year and beyond. Thus, it could be wise to invest in quality pharma stocks Ipsen (IPSEY), Supernus (SUPN), and Kamada (KMDA), which are…

StockNews.com

FDA Approves Expanded Use Of Supernus' Viloxazine In Adult ADHD Patients

The FDA approved an expanded indication for Supernus Pharmaceuticals Inc's (NASDAQ:SUPN) Qelbree (viloxazine extended-release capsules) for attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older. The FDA has now approved Qelbree for ADHD in children (starting at age 6), adolescents, and adults. Qelbree is a novel non-stimulant taken once daily for…

Benzinga

Looking Into Supernus Pharmaceuticals's Return On Invested Capital

According to Benzinga Pro data Supernus Pharmaceuticals (NASDAQ:SUPN) posted a 88.67% decrease in earnings from Q3. Sales, however, increased by 7.13% over the previous quarter to $159.05 million.

Benzinga

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

Neha PanjwaniFrom

97 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

125 stories

Health Canada

114 stories

Eli Lilly and Company

ACADIA Pharmaceuticals Inc

15 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.